PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34641722-2	2022	Lenvatinib is known to reduce angiogenesis and may overturn the immune-suppressive effects of VEGF in the tumor microenvironment.	lenvatinib	0-10	vascular endothelial growth factor A	Mus musculus	94-98	
30811474-1	2019	Lenvatinib is a multiple receptor tyrosine kinase inhibitor targeting mainly vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) receptors.	lenvatinib	0-10	vascular endothelial growth factor A	Mus musculus	77-111	
30811474-1	2019	Lenvatinib is a multiple receptor tyrosine kinase inhibitor targeting mainly vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) receptors.	lenvatinib	0-10	vascular endothelial growth factor A	Mus musculus	113-117	
25425971-4	2014	The inhibitory effect of E7080 on VEGF-induced angiogenesis was studied in an ex vivo mouse aortic ring angiogenesis assay.	lenvatinib	25-30	vascular endothelial growth factor A	Mus musculus	34-38